Long-Term Oncological Outcomes after Nerve-Sparing Robot-Assisted Radical Prostatectomy for High-Risk Localized Prostate Cancer: A Single-Center, Two-Arm Prospective Study

Lorenzo Spirito,Francesco Chessa,Anna Hagman,Anna Lantz,Giuseppe Celentano,Rodolfo Sanchez-Salas,Roberto La Rocca,Mats Olsson,Olof Akre,Vincenzo Mirone,Peter Wiklund
DOI: https://doi.org/10.3390/diagnostics14080803
IF: 3.6
2024-04-11
Diagnostics
Abstract:Aims: To compare the oncological outcomes of patients with high-risk localized prostate cancer undergoing nerve-sparing and non-nerve-sparing robot-assisted radical prostatectomy (RARP). Methods: Between November 2002 and December 2018, we prospectively recorded the data of patients undergoing RARP for high-risk localized prostate cancer (PCa) at our tertiary referral center. NSS (nerve-sparing surgery) was carefully offered on the basis of the preoperative clinical characteristics of the patients and an intraoperative assessment. The patients were stratified into two groups: nerve-sparing and non-nerve-sparing groups (yes/no). Radical prostatectomies were performed by 10 surgeons with a robot-assisted technique using a daVinci® surgical system. The primary oncological outcome evaluated was biochemical recurrence (BCR). The secondary oncological outcomes assessed were positive surgical margins (PSMs) and cancer-specific survival (CSS). Results: A total of 779 patients were included in the study: 429 (55.1%) underwent NSS while 350 (44.9%) underwent non-NSS. After a mean (±SD) follow-up of 192 (±14) months, 328 (42.1%) patients developed BCR; no significant difference was found between the NSS and non-NSS groups (156 vs. 172; p = 0.09). Both our univariable and multivariable analyses found that the nerve-sparing approach was not a predictor of BCR (p > 0.05). Kaplan–Mayer survival curves for BCR showed no significant difference among the non-NSS, unilateral NSS, and bilateral NSS groups (log rank test = 0.6). PSMs were reported after RARPs for 254 (32.6%) patients, with no significant difference between the NSS and non-NSS group (143 vs. 111; p = 0.5). In the subgroup of 15 patients who died during the follow-up period, mean (±SD) CSS was 70.5 (±26.1) months, with no significant difference between the NSS and non-NSS groups (mean CSS: 70.3 vs. 70.7 months). Conclusions: NSS does not appear to negatively impact the oncological outcomes of patients with high-risk PCa. Randomized clinical trials are needed to confirm our promising findings.
medicine, general & internal
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: to compare the long - term oncological outcomes of high - risk localized prostate cancer patients after receiving nerve - sparing and non - nerve - sparing robot - assisted radical prostatectomy. Specifically, the study aims to evaluate the effects of the two surgical methods on patients' biochemical recurrence rate (BCR), positive surgical margin rate (PSMs) and cancer - specific survival rate (CSS). ### Research Background Although radical prostatectomy (RP) is the standard treatment for localized prostate cancer, traditionally, for high - risk prostate cancer patients, surgery may be less popular than radiotherapy plus androgen deprivation therapy (ADT) because of the expected poor oncological and functional outcomes in these patients. However, some studies have shown that in carefully selected high - risk patients, surgery is acceptable, especially in the context of multimodal treatment. ### Research Objectives The main objective of this paper is to compare the oncological outcomes of high - risk localized prostate cancer patients after receiving nerve - sparing (NS) and non - nerve - sparing (non - NS) robot - assisted radical prostatectomy (RARP). ### Methods - **Research Design**: This is a single - center, two - arm prospective study, including high - risk localized prostate cancer patients who received RARP at a tertiary referral center from November 2002 to December 2018. - **Patient Grouping**: According to whether nerve - sparing surgery was performed, patients were divided into two groups: the nerve - sparing group and the non - nerve - sparing group. - **Primary Oncological Outcome**: Biochemical recurrence rate (BCR). - **Secondary Oncological Outcomes**: Positive surgical margin rate (PSMs) and cancer - specific survival rate (CSS). ### Results - **Patient Characteristics**: A total of 779 patients were included, of which 429 (55.1%) received nerve - sparing surgery and 350 (44.9%) received non - nerve - sparing surgery. - **Biochemical Recurrence Rate**: After an average follow - up of 192 months, 328 (42.1%) patients had biochemical recurrence, and there was no significant difference between the two groups (p = 0.09). - **Positive Surgical Margin Rate**: 254 (32.6%) patients had positive margins found in postoperative pathological examinations, and there was no significant difference between the two groups (p = 0.5). - **Cancer - Specific Survival Rate**: The average CSS was 70.5 months, and there was no significant difference between the two groups (p>0.05). ### Conclusions Nerve - sparing surgery (NSS) does not have a negative impact on the oncological outcomes of high - risk localized prostate cancer patients. Further randomized controlled trials are needed to verify this preliminary finding. ### Formulas No complex mathematical, physical, chemical or biological formulas are involved in the article, so there is no need to present formulas in a special Markdown format.